| Similar Articles |
|---|
 |
The Motley Fool
March 13, 2006
Stephen D. Simpson |
Watson Pays Up to Stay in the Game Watson gets bigger, but how much better? The company is buying Andrx for $25 a share. Investors, take note.   |
The Motley Fool
February 28, 2007
Brian Lawler |
Worrisome Watson The maker of generic drugs could have a challenging year ahead. Investors, take note. |
The Motley Fool
September 6, 2005
W.D. Crotty |
An Anxious Time for Andrx Questions about its manufacturing lead the FDA to take action. The generic drug company's stock was the largest percentage loser on the Nasdaq this morning. |
The Motley Fool
February 21, 2008
Brian Orelli |
Watson Gets Less Generic Branded sales were up while generics fell for the year, which made Watson Pharmaceutical a more balanced company. |
The Motley Fool
February 9, 2004
Alyce Lomax |
High Hopes for Andrx Are hopeful investors jumping the gun on the drug maker's generic prospects? |
The Motley Fool
November 10, 2006
Brian Lawler |
Watson Doesn't Wow Investors The generic drug developer made a $2 billion buyout of smaller competitor Andrx and finally closed the deal this quarter. Investors, take note. |
The Motley Fool
August 3, 2007
Brian Orelli |
Watson Turns It Around The pharmaceutical's steady revenue growth results in positive income for the quarter. Investors, take note. |
The Motley Fool
November 26, 2008
Brian Orelli |
Watson Gets Some Hand-Me-Downs Much like discount stores, generic-drug makers are in a cutthroat low-margin business, where "larger" almost always means "better." |
The Motley Fool
July 8, 2008
Brian Orelli |
Now That's the Way to Spin Off a Company The two spin-off companies formed from Abraxis Pharmaceutical, APP Pharmaceuticals and Abraxis BioScience, are worth almost double the value their parent had before the sale. |
BusinessWeek
July 30, 2007
Gene G. Marcial |
A Breakup At Brink's? Activist shareholders have upped pressure to spin off to shareholders the home security unit, so it can trade independently of the armored cars. |
The Motley Fool
June 28, 2004
Jeff Hwang |
Watson Pharmaceuticals Tumbles The generic drug business at Watson Pharmaceuticals is still going strong; it's the branded products that are causing trouble. |
The Motley Fool
November 5, 2004
Roger Nusbaum |
The Tale of Teva Generic drug companies like Teva may offer a smart way to own health care. However, the company's good fortune hit a bump when rival Andrx got pummeled with a bad earnings announcement, and Teva traded down in sympathy. |
The Motley Fool
January 3, 2008
Brian Orelli |
8 Generic-Drug Makers for 2008 Generic-drug makers can predict the growth of their industry, because it's written right in the patent-expirations column of the FDA's orange book. Here's a brief look at eight generic-drug makers worth closer scrutiny. |
The Motley Fool
January 20, 2005
Stephen D. Simpson |
Novartis Posts a Swiss Miss The Swiss drug giant has a strong pipeline, but moderate growth and high valuation suggest little room for error. |
